Popular

Buy Retatrutide 15mg

Name: Buy Retatrutide 15mg |$119 only| 99% Purity| COA Available
Price: 119.00 USD
Availability: InStock

15mg | Third-Party Tested | 99% Purity | COA Available | Research Use Only

$119.00

0 out of 5 · 0 ratings

Be the first to rate this compound:

11 in stock

Retatrutide 15 mg For Sale

Retatrutide is an investigational synthetic peptide. It is also known as LY3437943. Eli Lilly developed this compound. Retatrutide acts on three receptor pathways. These include GLP-1, GIP, and glucagon receptors. For this reason, it is described as a triple receptor agonist. Researchers study retatrutide in metabolic disease models, including obesity, type 2 diabetes, NAFLD, and MASH. Retatrutide is a long-acting popular peptide with an approximate half-life of six days. Clinical research protocols utilize subcutaneous administration, allowing once-weekly dosing in trials. As of 2026, retatrutide remains in Phase 3 clinical development under the TRIUMPH program. It is not approved by the FDA, EMA, or MHRA and is not authorized for commercial sale or personal use. It is intended strictly for research purposes, including in vitro studies, animal models, and approved clinical trials.

Retatrutide Mechanism of Action in Research Models

Retatrutide functions as a balanced triple agonist at GLP-1, GIP, and glucagon receptors with nanomolar binding affinity.

Reported EC50 Values (Approximate)

GIP receptor: ~0.064 nM
GLP-1 receptor: ~0.775 nM
Glucagon receptor: ~5.79 nM

In research models, retatrutide activates multiple metabolic pathways:

GLP-1 receptor activation reduces appetite via central signaling, slows gastric emptying, increases glucose-dependent insulin secretion, and suppresses glucagon during hyperglycemia.
GIP receptor activation enhances insulin secretion, supports beta-cell function, and influences adipose metabolism.
Glucagon receptor activation increases energy expenditure, stimulates hepatic glycogen breakdown, promotes lipolysis, and supports fat oxidation.

The combined receptor activity contributes to reduced caloric intake, improved insulin sensitivity, and increased metabolic rate. Studies report greater reductions in fat mass relative to lean mass. This triple-agonist profile differs from single or dual incretin agonists.

Retatrutide Peptide Structure and Properties

Retatrutide (LY3437943) is a synthetic peptide containing 39 amino acids. It is designed to interact with three receptors: GLP-1, GIP, and glucagon receptors. Its structure includes amino acid modifications and a fatty acid side chain that influence its stability and receptor activity.

Chemical Properties of Retatrutide

Property	Correct Information
Compound Name	Retatrutide
Research Code	LY3437943
Molecular Formula	C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight	Approximately 4,731 g/mol
CAS Number	2381089-83-2
PubChem CID	171390338 (Triple G structural record)
Amino Acid Length	39 residues
Peptide Type	Synthetic lipidated peptide
Receptor Targets	GLP-1R, GIPR, and GCGR
Physical Form	Lyophilized powder (supplier-dependent)
Research Status	Investigational compound

The molecular formula, molecular weight, and CAS number are supported by published chemical records.

Different Variations of Retatrutide at Orion Peptides:

Research Findings on Retatrutide

1. Obesity Research

A Phase 2 randomized trial published in the New England Journal of Medicine evaluated 338 adults with obesity or overweight with comorbidities. Once-weekly retatrutide demonstrated dose-dependent weight reduction. At 48 weeks, the 12 mg dose achieved approximately 24% mean weight loss. A majority of participants achieved clinically significant weight-loss thresholds. Improvements were also observed in waist circumference, lipid markers, and blood pressure.

2. Type 2 Diabetes Research

Phase 2 data reported HbA1c reductions of up to 2.02%, alongside substantial weight loss, compared to placebo groups.

3. Liver Fat and NAFLD Models

In participants with elevated hepatic fat content, retatrutide reduced liver fat significantly, with many high-dose participants reaching normalized levels.

Additional Research Areas

Phase 3 TRIUMPH trials are evaluating cardiovascular outcomes, osteoarthritis, kidney disease, and MASH. Some studies report weight reduction approaching 29% at 68 weeks. Additional endpoints include cardiometabolic markers and joint pain outcomes. Reported adverse effects in trials are primarily mild gastrointestinal events (nausea, diarrhea, vomiting) that are dose-related and typically improve with titration. Serious adverse events remain uncommon in published data.

Storage and Handling (Research Use)

Store unopened vials at 2–8°C and protect from light and moisture. Do not freeze the lyophilized powder. Reconstitute under sterile laboratory conditions using appropriate diluents according to research protocols. Refrigerate reconstituted solutions and use within validated stability windows. Follow institutional guidelines and use appropriate protective equipment.

Disclaimer

Retatrutide is an investigational compound currently in Phase 3 clinical trials. It is not approved for prescription use, commercial sale, compounding, or personal administration. Compounds marketed outside approved clinical research settings may be counterfeit and pose significant safety risks. No claims are made regarding safety or efficacy. Use is restricted to qualified research environments. Human studies require IRB or ethics approval and regulatory compliance.

Referenced Citations

Research Use Only

This compound is intended for laboratory research use only. It is not intended for human or animal consumption, or for use in diagnostic or therapeutic procedures.

Chemical Properties

Property	Value
Molecular Formula	C221H342N46O68
Molecular Mass	4731 g/mol
Monoisotopic Mass	4728.4717592 Da
Polar Surface Area	1780 Å²
Complexity	11500
XLogP	-6.3
Heavy Atom Count	335
Hydrogen Bond Donor Count	58
Hydrogen Bond Acceptor Count	70
Rotatable Bond Count	159
PubChem CID	171390338
InChI	InChI=1S/C221H342N46O68/c1-23-124(11)179(208(322)241-144(83-88-176(291)292)192(306)245-150(105-134-69-75-137(276)76-70-134)196(310)244-148(100-121(5)6)194(308)243-147(99-120(3)4)193(307)240-142(82-87-175(289)290)187(301)230-110-169(282)229-113-173(286)264-92-51-61-161(264)206(320)253-158(116-270)203(317)251-157(115-269)189(303)232-111-170(283)233-128(15)212(326)266-94-53-63-163(266)214(328)267-95-54-64-164(267)213(327)265-93-52-62-162(265)207(321)250-156(114-268)183(226)297)258-200(314)152(103-131-55-41-39-42-56-131)242-185(299)127(14)235-216(331)219(18,19)262-205(319)145(80-85-166(225)279)237-184(298)126(13)234-190(304)140(60-48-50-90-227-172(285)119-335-98-97-334-96-91-228-167(280)86-81-146(215(329)330)236-168(281)65-45-37-35-33-31-29-27-25-26-28-30-32-34-36-38-46-66-174(287)288)238-191(305)141(59-47-49-89-222)239-198(312)154(107-177(293)294)247-195(309)149(101-122(7)8)256-218(333)221(22,109-123(9)10)263-211(325)180(125(12)24-2)259-204(318)160(118-272)252-197(311)151(106-135-71-77-138(277)78-72-135)246-199(313)155(108-178(295)296)248-202(316)159(117-271)254-210(324)182(130(17)274)260-201(315)153(104-132-57-43-40-44-58-132)249-209(323)181(129(16)273)257-171(284)112-231-188(302)143(79-84-165(224)278)255-217(332)220(20,21)261-186(300)139(223)102-133-67-73-136(275)74-68-133/h39-44,55-58,67-78,120-130,139-164,179-182,268-277H,23-38,45-54,59-66,79-119,222-223H2,1-22H3,(H2,224,278)(H2,225,279)(H2,226,297)(H,227,285)(H,228,280)(H,229,282)(H,230,301)(H,231,302)(H,232,303)(H,233,283)(H,234,304)(H,235,331)(H,236,281)(H,237,298)(H,238,305)(H,239,312)(H,240,307)(H,241,322)(H,242,299)(H,243,308)(H,244,310)(H,245,306)(H,246,313)(H,247,309)(H,248,316)(H,249,323)(H,250,321)(H,251,317)(H,252,311)(H,253,320)(H,254,324)(H,255,332)(H,256,333)(H,257,284)(H,258,314)(H,259,318)(H,260,315)(H,261,300)(H,262,319)(H,263,325)(H,287,288)(H,289,290)(H,291,292)(H,293,294)(H,295,296)(H,329,330)/t124-,125-,126-,127-,128-,129+,130+,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,179?,180?,181-,182-,221+/m0/s1
InChIKey	MLOLQJNKXBNWFW-SAGGEDDASA-N
IUPAC Name	20-[[(1S)-4-[2-[2-[2-[[(5S)-5-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-2-methylpropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-2,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]-6-[[(2S)-1-[[(2S)-5-amino-1-[[1-[[(2S)-1-[[(2S)-1-[[(3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
SMILES	CC[C@H](C)C(C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N3CCC[C@H]3C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](C)NC(=O)C(C)(C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@](C)(CC(C)C)NC(=O)C([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC8=CC=CC=C8)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)C(C)(C)NC(=O)[C@H](CC9=CC=C(C=C9)O)N

Certificate of Analysis

Quality

Every batch of Buy Retatrutide 15mg is tested for purity and identity using industry-standard methods.

HPLC Analysis

High-Performance Liquid Chromatography confirms purity ≥99%. Each batch is analyzed to ensure consistent quality.

Mass Spectrometry (MS)

Identity verification via mass spectrometry confirms correct molecular weight of 4113.58 g/mol.

Third-Party Testing

All compounds undergo independent third-party laboratory testing for quality assurance.

Request COA

Certificate of Analysis documents are available for all compounds. Contact us with your order number to request batch-specific documentation.

COA Lab Tests

Each compound batch is tested by independent laboratories to verify purity, identity, and quality. The Certificate of Analysis (COA) provides transparent lab results, ensuring the compound meets strict research-grade standards.

Storage & Handling

Before Use (Uno⁠pened)

Store i‍n refri‌gerator at 2⁠°C‍ to 8°C, equivalent to‍ 36°F t‍o 46‌°F tem⁠perature r‌ange
Keep temperature consisten⁠t at a⁠ll‌ times

Store i‍n the main refrigerator compartment, avoid storing in the refrigerat⁠or do⁠or

‍Keep in o⁠ri⁠ginal p⁠a⁠c‍k⁠ag‌ing⁠ always

A‌fter Reconst‌itution (Liquid Form)

Continu⁠e⁠ refrigerat⁠ing⁠ at 2°‍C to 8°C⁠, 36°F and 46°F consistently
Ke‍ep the liquid form refrigerate‍d between dose‍s
R‌eturn to refrigerator immediately after use

Storage During Travel‌

‍Keep‌ in original packaging
Minimize time outside p‍roper storage
Retu⁠rn t⁠o refrigerator promptly upon arrival
Plan ahead for ext‍ended trav‌el

A‌fter Reconst‌itution (Liquid Form)

Continu⁠e⁠ refrigerat⁠ing⁠ at 2°‍C to 8°C⁠, 36°F and 46°F consistently
Ke‍ep the liquid form refrigerate‍d between dose‍s
R‌eturn to refrigerator immediately after use

Add

Test	Method	Result	Specification
Identity	HPLC-DAD	Retatrutide	Retatrutide	Pass
Purity	HPLC-DAD	99.27	>99% by HPLC	Pass
Quantity	HPLC Analyte Concentration Curve Assay	15.28	15mg	Pass
Endotoxins	LAL ELISA	0.048 EU/mL	≤ 0.5 EU/mL	Pass
Sterility	Pour Plate	No Growth	No Growth	Pass

Buy Retatrutide 15mg

Bulk Pricing – Save More

Retatrutide 15 mg For Sale

Retatrutide Mechanism of Action in Research Models

Reported EC50 Values (Approximate)

Retatrutide Peptide Structure and Properties

Chemical Properties of Retatrutide

Different Variations of Retatrutide at Orion Peptides:

Research Findings on Retatrutide

1. Obesity Research

2. Type 2 Diabetes Research

3. Liver Fat and NAFLD Models

Additional Research Areas

Storage and Handling (Research Use)

Disclaimer

Referenced Citations

Research Use Only

Chemical Properties

Certificate of Analysis

Quality

HPLC Analysis

Mass Spectrometry (MS)

Third-Party Testing

Request COA

COA Lab Tests

Storage & Handling

Before Use (Uno⁠pened)

A‌fter Reconst‌itution (Liquid Form)

Storage During Travel‌

A‌fter Reconst‌itution (Liquid Form)

Related Compounds

Storage

Certificate of Analysis